Have a personal or library account? Click to login
Rituximab in the treatment of Pembrolizumab induced Myasthenia Gravis Cover

Rituximab in the treatment of Pembrolizumab induced Myasthenia Gravis

Australasian Journal of Neuroscience
Volume 32 (2022): Issue 1 (May 2022)
By: Jessica C. O’Keeffe,  Nadia Deborah Friedman and  Sujith Ayyappan  
Open Access
|Jul 2022

Authors

Jessica C. O’Keeffe

jessicawisely6@gmail.com

Department of General Medicine, University Hospital Geelong, Victoria, Australia

Nadia Deborah Friedman

Department of Infectious Diseases, University Hospital Geelong, Victoria, Australia

Sujith Ayyappan

Department of Neurology, University Hospital Geelong, Victoria, Australia
DOI: https://doi.org/10.21307/ajon-2022-002 | Journal eISSN: 2208-6781 | Journal ISSN: 1032-335X
Journal RSS Feed
Language: English
Page range: 5 - 11
Published on: Jul 11, 2022
Published by: Australasian Neuroscience Nurses Association
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Keywords:
Rituximab,
Myasthenia Gravis,
Pembrolizumab,
Immune-related adverse events
Related subjects:
Medicine,
Basic medical science,
Basic medical science, other

© 2022 Jessica C. O’Keeffe, Nadia Deborah Friedman, Sujith Ayyappan, published by Australasian Neuroscience Nurses Association
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 32 (2022): Issue 1 (May 2022)Next article